Cost-effectiveness of Prosigna for Adjuvant Treatment Decisions in Early Breast Cancer: Healthcare Sector and Societal Perspectives. - Asphaug L; Akslen LA; Blix ES; Boge B; Borgen EF; Brekke MB; Falk RS; Geitvik GA; Gilje B; Gravdehaug B; Heie A; Janssen E; et al. (Clinical breast cancer, 2025)